ProCE Banner Activity

A Walk in the PARP: Therapeutic Strategies Targeting DNA Repair Defects in Prostate Cancer

Multimedia
Watch this CME-certified on-demand Webcast of a CCO symposium at ASCO GU 2019 to gain expert perspectives on the evolving role of PARP inhibitors in advanced prostate cancer, including an overview of BRCA and other DNA repair deficiencies, guidance on genetic testing, review of the latest clinical data, and a panel case discussion.

Released: March 20, 2019

Expiration: March 18, 2020

No longer available for credit.

Share

Faculty

Celestia S. Higano

Celestia S. Higano, MD, FACP

Professor
University of Washington
Departments of Urology and Medicine
Member
Fred Hutchinson Cancer Research Center
Seattle, Washington

David A. Quigley

David A. Quigley, PhD

Assistant Adjunct Professor
Department of Epidemiology and Biostatistics
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Charles Ryan

Charles Ryan, MD

Associate Clinical Professor
Department of Medicine Hematology/Oncology
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Clovis Oncology

Pfizer, Inc.

Learning Objectives

  • Describe the rationale and process for assessing germline and somatic DNA repair pathway alterations in prostate cancer
  • Examine the mechanism of PARP inhibition to achieve “synthetic lethality” in prostate cancer with deficient DNA damage response
  • Evaluate the available clinical evidence for the use of PARP inhibitors to treat metastatic CRPC harboring BRCA1/2 or other DNA damage response mutations
  • Identify patients suitable for enrollment on ongoing clinical studies investigating PARP inhibitor monotherapy or in combination with other agents in prostate cancer

Faculty Disclosure

Primary Author

Celestia S. Higano, MD, FACP

Professor
University of Washington
Departments of Urology and Medicine
Member
Fred Hutchinson Cancer Research Center
Seattle, Washington

Celestia (Tia) S. Higano, MD, FACP, has disclosed that she has received consulting fees from Astellas, Bayer, Blue Earth Diagnostics, Clovis Oncology, Ferring, Hinova, Janssen, Myriad Genetics, Orion Corporation, and Tolmar and that her partner/spouse has been employed in a leadership position by and has ownership interest in CTI Biopharma.

David A. Quigley, PhD

Assistant Adjunct Professor
Department of Epidemiology and Biostatistics
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

David A. Quigley, PhD, has no real or apparent conflicts of interest to report.

Charles Ryan, MD

Associate Clinical Professor
Department of Medicine Hematology/Oncology
University of California, San Francisco
San Francisco, California

Charles J. Ryan, MD, has disclosed that he has received consulting fees from Bayer, Clovis Oncology, Janssen, and Sanofi Genzyme; has received funds for research support from Clovis Oncology and the Prostate Cancer Foundation; has received fees for non-CME/CE services from Janssen; and has served in a study leadership position for Clovis Oncology.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.